Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment

Robin C Wackernah
Matthew J Minnick
Peter Clapp

1Department of Pharmacy Practice, 2Department of Pharmaceutical Sciences, School of Pharmacy, Rueckert-Hartman College for Health Professions, Regis University, Denver, CO, USA

Abstract: Alcohol use disorders (AUD) continue to be a concerning health issue worldwide. Harmful alcohol use leads to 2.5 million deaths annually worldwide. Multiple options exist for the management of dependence on alcohol, not all of which are approved by drug-regulating agencies. Current practice in treating AUD does not reflect the diversity of pharmacologic options that have potential to provide benefit, and guidance for clinicians is limited. Few medications are approved for treatment of AUD, and these have exhibited small and/or inconsistent effects in broad patient populations with diverse drinking patterns. The need for continued research into the treatment of this disease is evident in order to provide patients with more specific and effective options. This review describes the neurobiological mechanisms of AUD that are amenable to treatment and drug therapies that target pathophysiological conditions of AUD to reduce drinking. In addition, current literature on pharmacologic (both approved and non-approved) treatment options for AUD offered in the United States and elsewhere are reviewed. The aim is to inform clinicians regarding the options for alcohol abuse treatment, keeping in mind that not all treatments are completely successful in reducing craving or heavy drinking or increasing abstinence.

Keywords: abuse, alcohol, alcoholism, craving, dependence, relapse

Introduction

Alcoholic beverages are consumed around the world as an acceptable part of many recreational and ceremonial activities. Low-to-moderate use of alcohol may facilitate socialization, as it reduces anxiety and has a disinhibiting effect on social behaviors. Compared to other drugs of abuse, relatively large amounts of alcohol are required to produce physiological effects. Consider that the average drink contains 14 grams of ethanol,1 whereas a tobacco cigarette or a tablet of oxycodone hydrochloride contains only milligram quantities of the active substance. The US National Institute on Alcohol Abuse and Alcoholism defines “heavy drinking” as consuming more than four drinks a day or 14 drinks a week for males, and consuming more than three drinks a day or seven drinks a week for females. It is estimated that one in four heavy drinkers have alcohol-related problems, such as dependence.1

Addiction treatment trials often use the Diagnostic and Statistical Manual of Mental Disorders (Text Revision), 4th edition (DSM-IV-TR) definition of alcohol use disorders ([AUD] abuse or dependence) to define study participants. The DSM-IV definition of alcohol dependence requires significantly harmful impact caused by at least three out of seven target conditions within a single year. These dependence symptoms include tolerance; withdrawal; increased amounts of alcohol consumed...
over time; ineffective efforts to reduce use; interference with personal or professional life; significant amount of time spent obtaining, using, and recovering from alcohol; or continued use of alcohol despite harmful sequelae. Alcohol abuse is defined broadly and requires the presence of at least one of the four abuse criteria for diagnosis.

The DSM-5, which was released in May 2013, has combined criteria for alcohol dependence and abuse into a single term (AUD). Craving was added as a diagnostic criteria and at least two target conditions are now required for diagnosis of AUD. New International Statistical Classification of Diseases and Related Health Problems (ICD) 10 codes that correspond to DSM-5 will be used beginning in October 2014. The majority of clinical trials in this review include subjects with DSM-IV alcohol dependence diagnosis.

Although approved pharmacologic treatment options for patients with AUD are limited in number, recent trials describe a host of alternative approaches to reducing alcohol consumption. These include the use of antipsychotics, antidepressants, anticonvulsants, and others, under the rationale that these drugs target the neurotransmitter systems that have been shown to undergo changes with chronic exposure to alcohol. This review describes current evidence for the clinical use of a broader range of pharmacotherapies in AUD, along with available information on patient characteristics (eg, genetic, demographic, behavioral) that may predict positive outcomes of treatment.

Methods
Clinical trials associated with alcohol abuse or dependence were identified using PubMed, Ovid, Cochrane Library, and MEDLINE. Search terms included “alcohol abuse,” “alcoholism,” “antipsychotics,” “antidepressants,” “anticonvulsants,” and “treatments for alcohol use disorders” through October 2013. Articles that focus on alcohol detoxification and managing alcohol withdrawal syndrome were excluded, as this topic is outside the scope of this review. Medications within and outside the United States are included in this review. Only articles available in English are included. Studies using dual diagnosis, articles older than 10 years, uncontrolled trials, and review articles were excluded, except where noted.

Neurobiology and pathophysiology of AUD
The acute and chronic effects of alcohol on brain physiology have been well studied and help to rationalize the investigation of psychotropic drugs in the treatment of AUD. In particular, neurotransmitter pathways involved in learning and reward have proven to be effective targets, based on the mechanisms of action of two currently approved AUD drugs, acamprosate and naltrexone. Other compounds under current investigation similarly produce effects by targeting monoamine (eg, serotonin [5-HT], norepinephrine, dopamine) or amino acid (eg, glutamate, γ-aminobutyric acid [GABA]) neurotransmitters.

Alcohol neuroadaptation and reward
Alcohol, like other addictive drugs, stimulates release of the neurotransmitter dopamine from cells originating in a region of the brain called the ventral tegmental area (VTA). The VTA is a component of a neuronal circuit called the mesolimbic dopamine system that has been associated with behavioral motivation and reward. Following exposure to alcohol, dopamine released into the nucleus accumbens (NAC) and prefrontal cortex has been postulated to reinforce drinking behaviors or make the experience of drinking more salient. Recent reviews of the neurobiological literature have described evidence that neuronal plasticity and metaplasticity in the mesolimbic system can promote reward-based learning and the development of addiction. Whereas alcohol does not appear to selectively bind dopamine receptors, its effects on dopamine release are likely mediated through interactions with other neurotransmitter systems, such as glutamate, GABA, corticotropin-releasing factor, and 5-HT, as well as through interactions with the endogenous opioid system (eg, endorphins, enkephalins).

Electrochemical activation of neurons is controlled by a balance between excitatory and inhibitory neurotransmitters. Acutely, alcohol inhibits the flow of ions through N-methyl-D-aspartate (NMDA)-type glutamate receptors and enhances the activity of GABA receptor channels, producing an overall inhibitory effect on neurons. Chronic exposure to alcohol promotes neuroadaptive responses that increase the potential excitability of neurons through upregulation or trafficking of NMDA receptors. Changes in glutamate signaling pathways associated with chronic exposure to alcohol may enhance the response to cues associated with drinking. Plasticity at glutamatergic synapses on dopamine neurons exists in many forms and may regulate how efficiently drug-related events and actions affect vulnerability to developing addiction. Furthermore, changing the balance between glutamate and GABA signaling establishes a state of hyperexcitability that is manifest upon cessation of drinking and that may contribute to the negative symptoms of alcohol withdrawal. Changes in the GABA system contribute to the anxiogenic and aversive
effects of alcohol withdrawal and can persist over long
periods of abstinence from alcohol. The desire to relieve anxi-
ety and negative sensations of withdrawal can contribute to
relapse to drinking and lead to the repetitive and compulsive
behaviors that characterize alcohol dependence.9

Pharmacologic strategies to reduce drinking in patients
with AUD may attempt to correct the imbalance between
excitatory and inhibitory pathways, and relieve the intense
craving for alcohol brought about by neuroadaptation.
Alternatively, compounds that target reward pathways may
compensate for the plasticity in dopamine signaling that
enhances the drinking experience of patients with AUD.

In spite of increasing knowledge of the neurobiological
disturbances caused by habitual drinking, a common etiolo-

Pathophysiological consequences
of alcohol use

Even in otherwise healthy individuals, alcohol is toxic to most
organ systems at doses above one to two drinks per day.11
Long-term exposure to alcohol generally increases the risk of
damage to the gastrointestinal, cardiovascular, immune,
nervous, and other systems. Cellular toxicity can be initiated
by the metabolism of ethanol and subsequent accumulation
of acetaldehyde, a metabolite that can damage intracellular
proteins and induce cell death through apoptosis.11
Additionally, changes in the oxidation–reduction state of a
cell following substantial ethanol metabolism can have an
impact on cellular respiration and the metabolism of fats in
both animals and humans.12

Alcohol can promote gastrointestinal bleeding through
inflammation of the esophagus and stomach, or through
vomiting that can damage the gastrointestinal mucosa. Acute
pancreatitis is more prevalent in alcoholics than in the general
population and can progress to chronic disease or pancreatic
cancer with prolonged exposure.12 Accumulation of fat in
the liver as a result of decreased oxidation of fatty acids and
other metabolic changes can progress to fatty liver disease,
alcohol-induced hepatitis, and cirrhosis.14

Low-to-moderate alcohol consumption (one to two drinks
per day) causes peripheral vasodilation and decreases con-
tractility of the heart, resulting in a mild decrease in blood
pressure.13 Changes in clotting mechanisms or increases
in high-density lipoprotein in alcohol users who typically
have one drink per day may even confer a cardioprotective
effect.16 However, consuming three or more drinks per day
is a factor in mild-to-moderate hypertension and heavy
drinkers are at increased risk for coronary artery disease and
cardiomyopathy. The effects of heavy drinking can range
from left ventricular impairment and arrhythmia to heart
failure as a result of limited contractility of heart muscle.
Binge drinking (eg, a single exposure to 90 mL of 80-proof
whiskey) can produce atrial or ventricular arrhythmias, even
in individuals who have no other evidence of heart disease,
a syndrome known as “holiday heart.”17

Alcohol-dependent individuals may experience periph-
ernal neuropathy characterized by tingling or numbness,
especially in the hands and feet. A progressive neurologic
syndrome that affects gait and stance, often accompanied by
nystagmus, can result from atrophy of the cerebellum due to
alcohol toxicity.18 Less common are neurologic syndromes
that result from thiamine deficiency secondary to heavy
drinking: Wernicke’s syndrome consists of encephalopathy,
uncoordinated muscle movement, and eye muscle weakness;
and Korsakoff’s syndrome is characterized by amnesia.

Demographics of alcohol use

Consumption of alcoholic beverages in the US is common,
with two-thirds of adults over 18 years of age having con-
sumed alcoholic beverages within the past year, according
to the 2011 National Health Interview survey.19 The highest
prevalence of heavy use (13.7%) is observed in the age group
from 18 to 25 years.20 Estimates in the general population are
similar or higher in Europe, according to the World Health
Organization.21

Severe repetitive problems with alcohol are reported to
have a lifetime risk in men of almost 20% and in women
of 10%–15%.22 Annual costs associated with health and
productivity problems caused by heavy drinking have been
estimated to be $185 billion in the US in recent years, and
this substance contributes to hundreds of thousands of
deaths annually in the US (ie, 2.1 deaths per 100,000) and
across Europe.20,21 Because of alcohol’s adverse effects on
several physiological systems and interactions with many
therapeutic medications, medical management and patient
care is greatly impacted by modern, heavy levels of alcohol
consumption.23

Pharmacotherapy: approved
medications for AUD

Pharmacologic strategies for treating alcohol dependence
include generating an aversive physiological reaction to
alcohol to mask positive subjective effects and administering medications that block alcohol reinforcement. Medications that target the reward pathways in the brain have been suggested to normalize adaptations to chronic alcohol exposure and reduce craving for alcohol. Other strategies aim to reduce negative symptoms of alcohol withdrawal that may promote relapse drinking by restoring the balance between inhibitory and excitatory neurotransmitter pathways. Three medications are currently approved by the US Food and Drug Administration for the treatment of alcohol dependence in adults: disulfiram, acamprosate, and naltrexone. Nalmefene is approved for alcohol dependence in Europe.

Disulfiram

The primary pharmacologic action of disulfiram involves the disruption of normal alcohol metabolism. After ethyl alcohol is absorbed by the body, it becomes converted to acetaldehyde, which is oxidized in the liver by the mitochondrial enzyme aldehyde dehydrogenase (ALDH). Disulfiram produces an irreversible inhibition of ALDH activity. When alcohol is ingested after taking disulfiram, acetaldehyde can accumulate to concentrations that are five to ten times higher than those found after consuming alcohol alone. The accumulation of acetaldehyde leads to unpleasant physiologic reactions including nausea, vomiting, flushing, rapid heartbeat, and falling blood pressure that deter continued drinking. The degree of response to the disulfiram–alcohol reaction increases with the dose of disulfiram and blood alcohol concentration, but even small amounts of alcohol consumed with disulfiram can produce mild reactions.

Due to the adverse effects of the ethanol–disulfiram reaction, disulfiram has the greatest potential for benefit in alcohol-dependent patients who are highly motivated to quit drinking. Patients must set a goal of abstinence when initiating disulfiram therapy, and providers should encourage patients to establish the resources and self-motivation to maintain abstinence once the drug is discontinued. Noncompliance is one of the biggest challenges in the use of disulfiram, illustrated by the 20% compliance measure in the largest controlled trial to date, administered among male US veterans. A very recent, single-blind trial in Japanese males with AUD demonstrated improved rates of abstinence only among subjects with an inactive ALDH2 allele. Disulfiram should be used with caution in patients with liver disease due to rare but fatal cases of hepatitis, and it is contraindicated for those with cardiac disease due to hypotension during the disulfiram reaction.

The clinical efficacy of disulfiram to reduce craving and prevent relapse to drinking may be related to changes in neurotransmission. Metabolites of disulfiram can alter neurotransmitter levels in the NAc that are implicated in the response to alcohol, and other studies suggest the acetaldehyde reaction may not be necessary to achieve favorable treatment outcomes.

Acamprosate

Acamprosate has been approved for use in alcohol-dependent individuals since 2004. Acamprosate is structurally similar to the endogenous amino acids (eg, glutamate, GABA, glycine) that act as neurotransmitters or neuromodulators in several different brain regions. The primary beneficial mechanism of action remains unclear; however, acamprosate is believed to normalize the balance between excitatory and inhibitory pathways that become adapted to chronic alcohol use and alleviate psychological and physiological discomfort that follows withdrawal. These effects may be due to some combination of antagonizing NMDA glutamate receptors, modulating type 5 metabotropic glutamate receptors, or reducing glutamate accumulation during repeated episodes of alcohol withdrawal.

Initial findings from US multisite studies, including the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) trial, differed significantly from earlier European trials, showing no benefit for acamprosate when compared to placebo in reducing alcohol use in treatment-seeking alcoholics. The recent PREDICT trial found no effect of acamprosate in extending time to first heavy drinking day among a predominantly male German patient population that had undergone inpatient treatment prior to enrollment, including an average 18 days of lead-in abstinence. It is possible that the high percentage of abstinent days across all groups in the COMBINE and PREDICT trials masked any benefit of acamprosate to promote abstinence above the combined behavioral intervention and/or medical management provided to all subjects. Large placebo effects are common in AUD trials, making the demonstration of significant effect sizes difficult. Primary care patients in the US also failed to benefit from acamprosate treatment, but exhibited a higher percentage of days abstinent during the study if they expressed a goal of abstinence at baseline. Meta-analysis of the European trial database, consisting primarily of middle-aged males with 7 years or more of dependence on alcohol, confirmed significant improvements in abstinence rates, percent days abstinent, and time to first drink with acamprosate treatment. Acamprosate also has a favorable safety and tolerability profile.

Naltrexone

Naltrexone is available for oral or intramuscular administration to reduce the craving for alcohol. The clinical
efficacy of naltrexone is believed to be mediated through interactions between dopamine and the endogenous opioid neuropeptide systems. The endogenous opioids are involved in the expression of alcohol’s reinforcing effects and may promote drug-seeking behaviors. Naltrexone functions as a competitive antagonist at opioid receptors. In animal models, alcohol administration was shown to promote β-endorphin release in regions of the brain that are involved in reward. Relief of the tonic inhibiting effects of GABA neurons by β-endorphins in the VTA promotes dopaminergic signaling from this area of the brain to the NAc.

Naltrexone is relatively well tolerated, and the primary side effect is gastrointestinal discomfort. High doses have been suggested to increase the risk of hepatotoxicity, and because naltrexone is an antagonist that can precipitate opioid withdrawal syndrome, it is contraindicated in patients who currently use opioid drugs.

In the COMBINE trial, naltrexone demonstrated improvements in maintaining abstinence and reducing heavy drinking, especially in patients who received no behavioral intervention. Further analyses demonstrated high clinical efficacy in the use of naltrexone with psychotherapy for short treatment periods. PREDICT failed to show an effect of oral naltrexone on heavy drinking in a patient population with a greater duration of continuous abstinence prior to randomization. A recent multisite investigation of the efficacy of intramuscular naltrexone in a randomized, placebo-controlled trial found 25% reduction in the event rate of heavy drinking days, especially in males who had achieved 7 days of lead-in abstinence. A secondary analysis revealed naltrexone effects on any drinking and complete abstinence in patients with a more clinically relevant period of 4 days lead-in abstinence. Direct comparison between oral and intramuscular administration has not been reported.

Nalmefene
Nalmefene is an opioid receptor modulator that is approved by the Committee for Medicinal Products for Human Use of the European Medicines Agency for use in the European Union. Nalmefene was approved for marketing in February 2013 and is approved for “the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level.” It works in a similar fashion to naltrexone, as an opioid antagonist at µ and δ receptors, and as an agonist at κ receptors. It is hypothesized that the blockade of opioid receptors interferes with the reinforcing effects of alcohol, in turn reducing alcohol cravings.

Nalmefene has been recorded to reduce the number of drinks per drinking day in alcohol-dependent subjects; however, when measuring days abstinent, number of heavy drinking days, time to relapse, and subjective cravings the data are controversial. While nalmefene may be superior to naltrexone in its ability to reduce alcohol cravings, and does not carry the same hepatotoxicity risk, its role in treating alcohol-dependent patients remains unclear.

Pharmacotherapy: non-approved medications for AUD
A variety of non-approved medications have been studied in the treatment of AUD. Medications like disulfiram and naltrexone have been associated with hepatic toxicity. This can be an issue with chronic drinking, as alcohol is associated with hepatotoxicity and 55% of deaths associated with alcohol are the result of liver disease. Acamprosate should be avoided in patients with severe renal impairment. Additionally, these medications are not effective in all patients for an indeterminate period of time, leading clinicians to seek additional options for the treatment of AUD.

Common measurements to determine the efficacy of medications for AUD include: percentage of drinking days; total amount of drinking; relapse; abstinence; cravings; and brain activation in the reward pathways of the brain.

Many published studies of non-approved medications included patients on psychotropic agents (eg, antipsychotics, antidepressants, anticonvulsants), suggesting the presence of a comorbid psychiatric illness and dual diagnosis of AUD with a mood or thought disorder. Dual diagnosis is an important and challenging issue, which can, however, introduce a number of variables that can lead to relapse. Clinical trials in patients with uncontrolled comorbid psychiatric diagnoses are not included in this review but can be found in other publications.

Antipsychotics
Antipsychotics are used for the treatment of schizophrenia and bipolar disorder and as adjunctive treatment for depression and autism. They block various dopamine receptors, and the second-generation antipsychotics are unique in that they also block 5-HT2 receptors. Due to dopamine’s implication in the reward pathways associated with AUD, these medications are targets for current research.

Aripiprazole
Aripiprazole at higher doses (23.3 mg daily) may be helpful in reducing number of drinks per day and reducing urges after follow-up drinks (15 mg daily); however, when
measuring number of heavy drinking days, days abstinent, and subjective craving. Aripiprazole performed poorly against placebo. Despite objective evidence that ventral striatum activation is blunted with aripiprazole, and that aripiprazole may be as efficacious as naltrexone in reducing craving and increasing time to relapse in patients with a goal of abstinence, its precise usefulness in alcohol-dependent patients is not clear.

**Olanzapine**

Olanzapine reduced alcohol cravings in young adult subjects (23 years average age) and reduced the number of drinks per day in AUD patients with higher baseline drinking habits, but only in individuals with the long version of the D4 dopamine receptor gene (DRD4). When studied in patients with no DRD4 allele stratification, 5–15 mg daily for 12 weeks was not different from placebo in reducing drinking measures. Given the minimal use of genetic information in AUD patient assessment, olanzapine may be considered on a trial-and-error basis in AUD.

**Quetiapine**

Quetiapine 400 mg daily for 6 weeks has shown positive results in drink reduction and impulsivity, and, over 12 weeks, demonstrated reduced drinking in type B alcoholics (early onset, more severe) compared to type A alcoholics (late onset, less severe). Quetiapine may not be useful in very heavy drinkers or as an adjunct to naltrexone, but may be an option to reduce drinking in less heavy drinkers or type B alcoholics.

**Other antipsychotics (flupenthixol, amisulpride, and tiapride)**

Flupenthixol intramuscular injection, amisulpride, and tiapride all performed poorly in placebo-controlled studies on measures of alcohol intake, craving, and abstinence.

**Antidepressants**

The majority of antidepressants studied in alcohol dependence use selective 5-HT reuptake inhibitors (SSRIs). These work by blocking the reuptake of 5-HT, allowing increased agonism of 5-HT receptors. 5-HT agonists have shown reduction in alcohol consumption in animal studies, and, due to these findings, may be a future option for AUD treatment.

**Citalopram**

Citalopram 40 mg has been found to reduce alcohol consumption in moderate drinkers, particularly in men; however, this effect did not carry over to very heavy drinkers. Potential lack of efficacy in very heavy drinking was further illustrated when subjects with lower baseline average daily drinking had 50% or more reduction in baseline drinking with citalopram 40 mg compared to subjects with higher daily drinking averages.

**Sertraline**

Sertraline 200 mg daily has been found to reduce drinking behaviors in type A alcoholic men; these results were not seen in type B alcoholic men or women. Sertraline’s efficacy in less severe alcohol dependence was again replicated in late-onset/low-vulnerability alcoholics who were homozygous for the long allele of the 5-HT transporter.

Its effectiveness as an adjunct to naltrexone is not clear. Trials that evaluated sertraline as adjunctive therapy to naltrexone used 100 mg compared to other trials where 200 mg was used when sertraline was tested as monotherapy in AUD.

**Fluoxetine**

Fluoxetine lacks consistent evidence for its usefulness in alcohol dependence. In undiagnosed alcohol-dependent patients, 60 mg daily of fluoxetine reduced total daily drinks and significantly reduced craving compared to baseline, but not to placebo; however, 60 mg did not affect abstinence or relapse rates in very heavy drinkers (average 18.6 drinks/day), nor reduce daily baseline or drinks per drinking day when compared to placebo. When dosed at 40 mg, fluoxetine did not reduce intake levels. At higher doses of 80 mg, daily fluoxetine reduced alcohol intake the initial week of a 4-week study.

**Anticonvulsants**

Anticonvulsants are used for seizure disorders and several have indications for chronic pain conditions and mood stabilization. They have a variety of mechanisms, including blockage of sodium channels, enhancing GABA, antagonizing glutamate receptors, and blocking calcium channels.

**Gabapentin**

Gabapentin titrated to 1,200 mg daily reduced craving after an alcohol cue, increased days abstinent in subjects with more severe alcohol withdrawal, reduced relapse to heavy drinking in patients with insomnia, and improved other drinking measures. Gabapentin 600 mg daily found positive benefits in very heavy drinkers. As an adjunct to naltrexone, gabapentin reduced total drinking and urges. Reduction in craving was not found in a real-world design amount of drinking.
Topiramate
In placebo-controlled, blinded studies using target doses of topiramate of 300 mg daily, topiramate outperformed placebo in multiple drinking measures and craving. Topiramate was equivalent to naltrexone in a blinded design measuring relapse and abstinence. Craving and intake were superior in naturalistic open designs.

Topiramate 150 mg daily was compared to disulfiram in a non-blinded randomized study. The study found disulfiram to be superior in abstinence and daily drinks, while topiramate significantly reduced craving compared to disulfiram, the lack of blinding and the low dose of topiramate, however, suggests that a more robust design with adequate topiramate dosing is warranted before drawing strong conclusions regarding the superiority of either medication. Topiramate can also be considered an effective adjunctive therapy in lower doses (75 mg daily) when combined with psychotherapy for alcohol dependence.

Levetiracetam
An open-label trial with levetiracetam on alcohol dependence found positive results; however, double-blind, placebo-controlled trials failed to find a benefit of levetiracetam for alcohol dependence. One study found that moderate-to-heavy drinkers taking levetiracetam increased their drinking during the study period.

Oxcarbazepine
Oxcarbazepine has been shown to be equivalent in efficacy to acamprosat and naltrexone in open-label studies comparing time to first relapse. At higher doses, 1,500–1,800 mg daily, oxcarbazepine was superior to naltrexone in a number of patients who remained alcohol-free. There are currently no placebo-controlled blinded studies testing oxcarbazepine’s place in alcohol dependence.

Divalproex sodium (VPA)
VPA significantly decreased relapse to heavy drinking in a blinded study against placebo and also decreased amount of drinking and craving compared to baseline. A small non-blinded study found VPA treatment increased abstinence at 6 weeks post-detoxification, though this was not statistically significant.

Other anticonvulsants (carbamazepine zonisamide, tiagabine, pregabalin)
Carbamazepine and zonisamide have placebo-controlled trials supporting their potential use in alcohol dependence. Zonisamide was significantly better than placebo in reducing number of heavy drinking days, reduction in number of drinks per week, and urge to drink. Days abstinent were similar to placebo. Similarly, carbamazepine outperformed placebo in longer time to relapse to heavy drinking.

Tiagabine and pregabalin both have open-label trials supporting their potential usefulness in alcohol dependence; however, placebo-controlled and head-to-head trials are needed to ascertain their particular place in therapy.

Other off-label medications
Ritanserin
Ritanserin is a 5-HT2 receptor antagonist with documented use to improve sleep, mood, and vigilance. The feedback inhibition of dopaminergic activity related to blocking 5-HT receptors may act as a substitute for alcohol effects. Multiple large clinical trials revealed poor results with ritanserin when compared to placebo when measuring daily drinks, craving in heavy drinkers, and relapse rates.

Baclofen
Baclofen is a skeletal muscle relaxant that is approved for use in muscle spasticity. It is a GABA-B agonist and, through this mechanism, the dopaminergic response to alcohol may be inhibited.

In addition to a 12-week open-label study, baclofen 30 mg daily has shown positive benefit compared to placebo in abstinence, craving, and daily alcohol intake. Higher doses (60 mg/day) produced a more robust response in reduction of number of drinks per day compared to 30 mg daily. Studies that failed to replicate the benefits of baclofen used patients with a lower daily drink intake and no comorbid liver problems who were recruited via advertisements as opposed to subjects seeking treatment.

Ondansetron
Ondansetron is an antiemetic medication that blocks 5-HT3 receptors. Due to alcohol’s activity on 5-HT3, it is thought that ondansetron can be a useful medication in alcohol dependence.

Ondansetron has been studied in four blinded placebo-controlled trials comparing low doses for alcohol dependence. Ondansetron significantly reduced daily drinking in light drinkers. No benefit was seen in heavy drinkers (≥10 drinks/day). Additional studies using weight-based dosing found benefits in craving, abstinence, and total drinks. One study showed increase in craving but reduced drinks per day. When used with naltrexone ondansetron,
0.5 mg reduced cue-induced craving and activation of the ventral striatum.124

Prazosin
Prazosin is an alpha 1-receptor adrenergic blocker that is used for the treatment of hypertension.125 At a titrated target dose of 16 mg daily, prazosin has been shown to reduce stress-induced craving.126 drinks per weeks, and drinking days.125 Simpson et al did not see a reduction in craving, though craving was not stress elicited.125

Varenicline
Varenicline is a nicotine agonist used for smoking cessation.127 Varenicline reduced number of drinks consumed, abstinence, and craving after a priming drink in a 2-hour session in smokers with AUD.127 It also reduced number of drinks per week and craving in a 16-week trial, but did not have an effect on total days abstinent.128

Kudzu extract
The kudzu root has been historically studied for its use in alcoholism; of particular interest are the extracts of the plant. The mechanism is not fully understood, but it is proposed that the extracts of the kudzu root may alter alcohol dehydrogenase or monoamine oxidase–acetaldehyde pathways,129,130 leading to reduced alcohol consumption.

Kudzu root extract was studied in non-treatment-seeking male drinkers over the course of a 4-week period. When compared to placebo, the kudzu extract reduced weekly alcohol consumption and increased the amount of consistent abstinence days.130 Additionally, puerarin (one of the three main isoflavones of the kudzu root) was found to reduce the amount of beer consumed when compared to placebo in non-diagnosed heavy drinkers.129 Both studies, however, indicate that the kudzu extract did not reduce subjective alcohol cravings,129,130 which may limit clinical use. The kudzu root extract appears to be beneficial in lowering alcohol consumption in heavy drinkers.

Conclusion
Disulfiram, naltrexone,acamprosate, and nalmefene all have benefits in the treatment of AUD. Considering the potential for treatment failure with approved pharmacological options or the inability to use a medication due to comorbid health conditions, a number of medications have been studied in AUD. For example, in the presence of a failed response to naltrexone or a contraindication (current opioid withdrawal) to its use, aripiprazole131 and topiramate129 both appear to be equal to naltrexone in efficacy for AUD. Perhaps the continued exploration of non-approved medications will result in the identification of a drug or combination of drugs that demonstrates generalized effectiveness in all AUD patient types.

Alternatively, heterogeneity of AUD patients and the complex etiology of the disease may preclude the discovery of such a drug. Varying patterns of consumption and differences in onset of drinking have defined AUD patient subtypes that respond differently to pharmacotherapy. Reported outcomes in subpopulations of study cohorts have followed a range of demographics, including sex and genetic background. Recognizing trends in current reports and strengthening associations between AUD subtypes and treatment outcomes with new studies may provide clinical guidance to prescribers in the near future. For example, an individual’s drinking goal (eg, controlled drinking, conditional abstinence, complete abstinence) established prior to treatment has been shown to be highly associated with clinical outcome, validating the importance of patient motivation for behavioral change.131 Clinical outcomes and drinking behavior just prior to treatment have also been shown to associate with medication effect. Acamprosate is slightly more efficacious in promoting abstinence than naltrexone, and it has a larger effect size in patients who have undergone detoxification.132 Naltrexone is slightly more efficacious in reducing heavy drinking than acamprosate, and it is associated with a larger medication effect in patients who enter treatment after a period of lead-in abstinence.132 Therefore, a patient’s drinking goals and current drinking status, as well as the intended clinical outcome, should be determined prior to treatment.

With regard to sex, although women with AUD enter treatment earlier in the course of the disease than men,133 clinical studies of pharmacologic AUD treatment tend to be comprised of mostly male patient populations. Treatment responses have been suggested in some cases to be better in men than women (eg, naltrexone,141 citalopram,72 and sertraline75), but a recent meta-analysis of over 50 naltrexone and acamprosate trials found no effect of sex on response to treatment.35 Although flupenthixol decanoate increased relapse rates among AUD patients, the risk was significantly lower in women than in men.62 Further AUD treatment studies that separate male and female populations are warranted.

Other examples of patient-specific criteria that might guide clinical decisions include the use of gabapentin in patients with comorbid insomnia,134 prazosin in patients who drink secondary to a stress response,126 and varenicline in patients who smoke,127,128 and data suggest olanzapine’s.
usefulness in patients with genetic predispositions related to the dopamine receptor gene.  

The influence of genetic background on patient response has been exemplified by the interaction between naltrexone response and polymorphisms in the μ opioid receptor gene OPRM1. In a review of the studies that included genetic information, Chamorro et al report that AUD patients who carry the A118G allele demonstrate lower rates of relapse to heavy drinking, with no change in abstinence. Evidence for a genetic influence on treatment response has also been reported for disulfiram, olanzapine, and ondansetron. As genetic testing becomes more cost-effective, it may represent a feasible strategy to tailor AUD treatments to an individual patient’s disease. The use of genetic information has become standard practice in other areas of medicine, including anticoagulation and oncology.

Research with well-designed studies will continue to be a necessity in the area of pharmacologic treatment for AUD. Based on the current state of AUD treatment research, it appears unlikely that a single agent or combination regimen will prove to be effective in all patients with AUD. Instead, clinicians may be obligated to match medication strategies to individuals or AUD subtypes, and this approach demands stronger evidence of treatment efficacy in particular patient groups.

Disclosure
The authors report no conflicts of interest in this work.

References


